Research programme: fibroblast autologous cell therapies - Fibrocell/Intrexon

Drug Profile

Research programme: fibroblast autologous cell therapies - Fibrocell/Intrexon

Alternative Names: FCX 013; Genetically-modified autologous fibroblasts - Fibrocell Science/Intrexon; genetically-modified human dermal fibroblast, collagen VII

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fibrocell Science
  • Developer Fibrocell Science; Intrexon Corporation
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cell replacements; Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Circumscribed scleroderma; Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Circumscribed scleroderma; Ehlers-Danlos syndrome; Eosinophilia; Psoriasis
  • Research Arthritis

Most Recent Events

  • 13 Nov 2017 Fibrocell plans a human safety clinical trial of FCX 013 in 2018
  • 12 Jun 2017 Fibrocell announces intention to submit IND application of FCX 013 to the US FDA in Q4-2017
  • 12 Jun 2017 FCX 013 receives Rare Paediatric Disease designation from the US FDA for Circumscribed scleroderma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top